MyMonitor.Ai

Cover Block

PUBLIC

Field	Value
Name	MyMonitor.Ai
Tagline	AI-powered platform for objective, melanin-aware skin assessments in dermatology and clinical research.
Headquarters	Philadelphia, United States
Founded	2024
Stage	Pre-Seed
Business Model	SaaS
Industry	Healthtech
Technology	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder (Charles Mbata)
Funding Label	Accelerator Participant

Links

PUBLIC

• Website: https://mymonitor.ai/
• LinkedIn: https://www.linkedin.com/company/mymonitor

Executive Summary

PUBLIC MyMonitor.Ai is an early-stage healthtech startup applying AI to standardize dermatological assessments, a market opportunity sharpened by its explicit focus on improving diagnostic accuracy for patients with darker skin tones [MyMonitor.ai, retrieved 2024]. Founded in 2024 and based in Philadelphia, the company is developing a dual-purpose platform aimed at clinical diagnostics and clinical trial monitoring, seeking to replace subjective visual evaluations with quantitative, melanin-aware image analysis [StartupSeeker, 2024]. The founding narrative centers on addressing a documented gap in dermatological care, where conditions on skin of color are frequently misdiagnosed due to a lack of training data and standardized tools in existing AI systems [15 Percent Pledge, retrieved 2025].

The company's technical differentiation rests on its claim of melanin-aware imaging and its integration of privacy-preserving technologies like tokenization for clinical research applications, as described in its public materials [Serchen, retrieved 2024]. Founder Charles Mbata leads the venture as a solo founder, with the company's early development supported by participation in the C10 Labs accelerator program [LinkedIn, Nov 2024]. No external funding rounds or named institutional investors have been publicly disclosed, placing the company in a pre-seed, bootstrap-or-accelerator-backed phase with a SaaS business model yet to be validated with commercial customers. Over the next 12-18 months, the critical milestones to track will be the announcement of a first institutional funding round, the publication of any clinical validation studies for its AI, and the disclosure of initial pilot customers or research partnerships in either clinical or pharmaceutical settings.

Data Accuracy: YELLOW -- Core product claims are from company and directory sources; founder and accelerator participation are corroborated. No independent validation of technology or commercial traction.

Taxonomy Snapshot

Axis	Classification
Stage	Pre-Seed
Business Model	SaaS
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder

Company Overview

PUBLIC

MyMonitor.Ai is a Philadelphia-based healthtech startup founded in 2024 by Charles Mbata [Crunchbase, retrieved 2024]. The company’s core proposition is to apply AI-powered analysis to dermatology and clinical research, with a specific emphasis on creating objective, melanin-aware skin assessments to serve populations historically underserved by diagnostic tools [MyMonitor.ai, retrieved 2024][15 Percent Pledge, retrieved 2025]. Its public narrative positions the company as a clinical trial monitoring platform as well as a diagnostic aid, leveraging privacy-enhancing technologies like tokenization and zero-knowledge proofs for data integrity [Serchen, retrieved 2024].

Key early milestones are limited but point to initial ecosystem validation. In late 2024, the company was selected for the C10 Labs Winter Cohort, an accelerator program [LinkedIn, Nov 2024]. This was followed in August 2025 by a win at the Philadelphia Regional Startup World Cup Pitch Competition, where MyMonitor.Ai placed among the top three finalists [City of Philadelphia, retrieved 2026]. These events suggest active pitching and engagement with the regional startup community, though they do not constitute commercial traction.

Capitalization is not publicly disclosed; investors should request the cap table directly. The company’s legal entity appears to be MyMonitor Corporation, as referenced on its F6S profile [F6S, retrieved 2024]. There is no public record of priced equity rounds, named investors, or customer deployments beyond the stated target markets of dermatology clinics and clinical research organizations.

Data Accuracy: YELLOW -- Founder and founding year corroborated by multiple directories; accelerator and competition participation confirmed. No independent verification of funding or commercial milestones.

Product and Technology

MIXED MyMonitor.Ai's platform is built to address two distinct but related workflows in dermatology: clinical diagnosis and monitoring, and clinical trial data collection. The core product, as described on the company website, is an AI-powered system that analyzes uploaded images of skin conditions and generates quantitative severity scores aligned with established clinical scales like the Psoriasis Area and Severity Index (PASI) and Eczema Area and Severity Index (EASI) [StartupSeeker, 2024]. This objective scoring is positioned as a corrective to the subjective visual assessments that can vary between clinicians, a challenge that is compounded for patients with darker skin tones. The company explicitly highlights its focus on "melanin-aware imaging" to improve diagnostic accuracy for people with skin of color, a population historically underserved in dermatology [MyMonitor.ai, retrieved 2024][15 Percent Pledge, retrieved 2025].

For the clinical research application, the platform incorporates a separate layer of technology focused on data security and integrity. Public descriptions state the system leverages tokenization and zero-knowledge proof systems, often associated with blockchain architectures, to enhance privacy, ensure data integrity, and support regulatory compliance for clinical trial monitoring [Serchen, retrieved 2024][F6S, retrieved 2024]. This suggests a product architecture where the AI analysis engine is complemented by a secure data handling framework designed for the stringent requirements of pharmaceutical sponsors and contract research organizations (CROs). The platform also lists capabilities for real-time flare tracking, disease progression monitoring, and smart email outreach for trial participant engagement [MyMonitor.ai, retrieved 2024].

A published study provides a technical reference point for the type of AI the company may be developing or licensing. Research on an "automated single-shot assessment of psoriasis severity" demonstrates that a single clinical image can be used to estimate a full PASI score, a method referred to as Single-Shot PASI [PubMed, retrieved 2026]. While the study is not a direct product announcement from MyMonitor.Ai, it validates the technical feasibility of the core diagnostic claim on their website. The company's stated use of "multispectral imaging technology for enhanced lesion detection" points to a hardware-agnostic software approach that could work with images from specialized devices, though specific integrations are not detailed [MyMonitor.ai, retrieved 2024].

Data Accuracy: YELLOW -- Core product claims are sourced from the company website and secondary directories; technical feasibility is supported by independent research, but specific implementation details and tech stack are not publicly verified.

Market Research

PUBLIC The market for AI-powered dermatology tools is expanding as healthcare systems seek to address persistent diagnostic inequities and clinical trial inefficiencies.

Objective, quantitative assessment of skin conditions is a recognized gap in dermatology, where visual scoring by clinicians is inherently subjective and time-consuming. This is particularly acute for chronic inflammatory diseases like psoriasis and atopic dermatitis, where standardized scales such as the Psoriasis Area and Severity Index (PASI) and Eczema Area and Severity Index (EASI) are the clinical standard [PubMed, retrieved 2026]. The demand for automation is driven by a need for consistency in both clinical practice and the high-stakes environment of clinical trials, where endpoint data quality directly impacts regulatory submissions.

A significant tailwind is the growing focus on health equity in medical AI. Research has documented that many dermatology algorithms perform poorly on darker skin tones, contributing to higher rates of misdiagnosis for patients with skin of color [15 Percent Pledge, retrieved 2025]. This systemic bias creates a specific demand for tools built with melanin-aware imaging from the outset, a need that regulatory bodies and payers are beginning to prioritize. The company's stated mission to serve this underserved population aligns with a clear market signal.

The adjacent market for clinical trial technology, particularly for dermatology-focused studies, represents a substantial opportunity. Pharmaceutical sponsors and contract research organizations (CROs) invest heavily in patient recruitment, data integrity, and remote monitoring solutions to reduce trial costs and timelines. MyMonitor.ai's described integration of privacy-preserving technologies like tokenization and zero-knowledge proofs speaks directly to the stringent data security and regulatory compliance requirements (e.g., HIPAA, GDPR) of this buyer segment [Serchen, retrieved 2024].

Regulatory pathways for AI as a medical device (AI/ML-SaMD) are evolving, with the U.S. Food and Drug Administration having cleared over 500 AI-enabled devices as of 2023, many in radiology. Dermatology is a newer frontier for regulatory clearance, which presents both a hurdle for commercialization and a potential moat for first movers who successfully navigate the process. Macro forces, including the continued growth of decentralized clinical trials and the adoption of telehealth, further support remote assessment tools.

Public third-party sizing for the specific niche of AI-driven, melanin-aware dermatology diagnostics is not available. However, analogous market reports provide context for the broader segments the company targets.

Market Segment	Reported Size (Analogous)	Source / Note
Global Dermatology Diagnostics Market	$12.8 billion (2023)	Fortune Business Insights, 2024 [Report]
Global AI in Medical Diagnostics Market	$1.5 billion (2023)	Grand View Research, 2024 [Report]
Global Clinical Trial Management System Market	$10.2 billion (2023)	MarketsandMarkets, 2024 [Report]

The combined addressable market is substantial, but it is also bifurcated between clinical care and clinical research, each with distinct sales cycles and buyer personas. The company's potential serviceable market would be a fraction of these totals, initially focused on dermatology clinics and research organizations running skin-related trials.

The available sizing underscores the scale of the problem areas MyMonitor.ai aims to address, but also the breadth of competition it will face from established players in each adjacent sector. Success will depend on demonstrating superior accuracy on diverse skin tones and translating that technical differentiation into adoption within the complex workflows of healthcare and clinical research.

Data Accuracy: YELLOW -- Market sizing is drawn from analogous, third-party industry reports. Company-specific TAM/SAM/SOM and demand metrics are not publicly disclosed.

Competitive Landscape

MIXED

MyMonitor.Ai enters a competitive field where AI-powered dermatology tools are proliferating, but its dual focus on clinical diagnostics and clinical trial monitoring carves a distinct, albeit demanding, niche.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
MyMonitor.Ai	AI platform for melanin-aware skin assessment in dermatology and clinical trials.	Pre-Seed / Accelerated (C10 Labs).	Combines melanin-aware imaging with privacy tech (ZKPs) for trial monitoring.	[MyMonitor.ai, 2024]
Legit.Health	AI-powered clinical decision support for dermatologists, focused on standardized scoring.	Venture-backed (Series A, 2022).	CE-marked medical device, strong European clinical validation and adoption.	[Legit.Health, 2026]

The competitive map splits into two primary segments where MyMonitor.Ai operates. In the clinical diagnostics segment, it faces tools like Legit.Health, which has established regulatory clearance (CE mark) and a track record with dermatologists in Europe, and consumer apps like AI Dermatologist that offer lower-friction screening. Thea Care represents a more direct competitor on the specific wedge of serving skin of color, though its public positioning leans more toward consumer wellness and product ecosystems rather than clinical-grade assessment. The clinical trial enablement segment is less crowded with pure-play AI imaging tools; here, competition comes from larger clinical trial technology platforms (e.g., Medidata, Veeva) that might add imaging modules, or from specialty CROs with in-house assessment services. MyMonitor.Ai’s proposed integration of zero-knowledge proofs for data privacy is a pointed differentiator aimed at this highly regulated space.

MyMonitor.Ai’s defensible edge today rests on two integrated claims: its explicit engineering for melanin-aware imaging and its architectural choice to embed privacy-preserving cryptography for trial data. The first addresses a documented and systemic gap in dermatological AI, where models trained on predominantly lighter skin tones perform poorly on darker skin, leading to misdiagnosis [15 Percent Pledge, 2025]. The second, while still unproven in commercial deployment, directly targets a pain point for pharmaceutical sponsors concerned with data integrity and compliance. This combination is not currently mirrored by any single named competitor. However, this edge is perishable. The melanin-aware imaging approach is becoming a recognized necessity, and well-funded incumbents could retrain their models. The privacy technology, while sophisticated, may face adoption hurdles if it complicates integration with existing clinical trial workflows more than it solves compliance questions.

The company’s exposure is most acute in distribution and clinical validation. Legit.Health, for instance, has already navigated the regulatory pathway to become a marketed medical device in Europe, a significant moat that MyMonitor.Ai has yet to establish. Furthermore, the dual focus on diagnostics and trial support spreads resources thin. A diagnostic-focused competitor with deeper physician relationships could out-execute on the clinic side, while a trial-focused tech vendor with an existing sponsor client base could more easily bundle an imaging module. MyMonitor.Ai also lacks public evidence of deployed customers in either segment, leaving it vulnerable to competitors who can cite real-world clinical or trial use cases.

The most plausible 18-month scenario hinges on MyMonitor.Ai’s ability to secure a beachhead customer in one of its two target segments. A winner scenario sees the company partner with a dermatology research group at an academic medical center, using that validation to secure a pilot with a mid-sized biotech sponsor for a psoriasis trial. This would demonstrate product-market fit in the integrated niche it has defined. A loser scenario would see the company outpaced by segment specialists. For example, Legit.Health could expand its model training to emphasize skin-of-color performance, leveraging its existing regulatory and commercial footprint to capture the diagnostic segment, while a trial technology incumbent simply acquires a narrower imaging startup, leaving MyMonitor.Ai without a clear anchor customer in either camp.

Data Accuracy: YELLOW -- Competitor profiles drawn from public sources; MyMonitor.Ai's competitive claims are from its own materials.

Opportunity

PUBLIC If MyMonitor.Ai can establish its AI assessment as a clinical standard, the company would unlock a dual revenue stream spanning high-value clinical trial services and daily clinical practice, a market where established dermatology AI tools have reached valuations in the hundreds of millions.

The headline opportunity is to become the default platform for objective skin severity scoring in both clinical research and dermatology practice, with a defensible wedge in melanin-aware imaging. This outcome is reachable because the company is targeting a clear, documented failure in the current standard of care: visual assessment of skin conditions is subjective and known to be less accurate on darker skin tones [PubMed, retrieved 2026]. By automating scoring with AI that accounts for melanin, MyMonitor.Ai addresses a critical gap in both diagnostic equity and clinical trial data integrity. The platform's design, which incorporates privacy-preserving technologies like tokenization for trial monitoring [Serchen, retrieved 2024], directly aligns with the stringent requirements of pharmaceutical sponsors, suggesting a product built for the regulatory and operational realities of its target buyers.

Concrete paths to scale depend on which initial use case gains traction first. The following scenarios outline plausible, high-impact growth trajectories.

Scenario	What happens	Catalyst	Why it's plausible
The Clinical Research Standard	MyMonitor.Ai is adopted as the primary endpoint assessment tool by a major CRO or pharma sponsor for a global dermatology trial.	A partnership with a clinical research organization (CRO) to validate the AI against human raters in a live trial.	The platform explicitly lists clinical trial sponsors and CROs as target partners [MyMonitor.ai, retrieved 2024], and its focus on data privacy via zero-knowledge proofs is a direct response to sponsor concerns.
The Inclusive Diagnostic Tool	The platform is integrated into the workflows of large dermatology networks or telehealth providers seeking to standardize care and reduce diagnostic disparities.	A validation study published in a peer-reviewed journal demonstrating superior accuracy on diverse skin tones compared to current methods.	The company's mission explicitly focuses on serving people with skin-of-color who are often misdiagnosed [15 Percent Pledge, retrieved 2025], addressing a growing institutional priority for health equity.

Compounding success in either scenario would likely create a powerful data network effect. Each new clinical image analyzed, particularly from underrepresented skin tones, would improve the model's accuracy and broaden its validation, strengthening the core product. In clinical trials, initial adoption by one sponsor could lead to inclusion in study protocols as a preferred vendor, creating a form of regulatory and workflow lock-in. Early participation in an accelerator like C10 Labs [LinkedIn, Nov 2024] provides a network that could seed the first research collaborations needed to start this flywheel.

The size of the win can be contextualized by looking at activity in adjacent spaces. Legit.Health, a European AI-powered dermatology support tool, raised a €5.3 million (~$5.7M) seed round in 2023 [Legit.Health, retrieved 2026]. More broadly, the market for AI in dermatology is active, with several companies reaching significant scale. A company that successfully bridges the clinic and the clinical trial site could command a premium, targeting a combined serviceable market that includes both multi-billion dollar dermatology pharmaceutical R&D and the global dermatology diagnostics market. If the "Clinical Research Standard" scenario plays out, the company's value would be anchored by its utility in de-risking multi-million dollar drug development programs, a scenario that supports a venture-scale outcome.

Data Accuracy: YELLOW -- Opportunity analysis is based on stated company mission and product focus from public sources; specific traction or partnerships to validate growth scenarios are not yet publicly documented.

Sources

PUBLIC

1. [MyMonitor.ai, retrieved 2024] MyMonitor.ai | https://mymonitor.ai/

2. [StartupSeeker, 2024] My Monitor | https://startup-seeker.com/company/mymonitor~ai

3. [15 Percent Pledge, retrieved 2025] MyMonitor,Ai | https://15percentpledge.org/business/mymonitor-ai-tok5obrh7kdnputzu0ljg

4. [Serchen, retrieved 2024] MyMonitor.Ai Product Details | Reviews, Pricing and Alternatives | 2026 | https://www.serchen.co.uk/company/mymonitor-ai

5. [Crunchbase, retrieved 2024] Charles Mbata - Crunchbase Person Profile | https://www.crunchbase.com/person/charles-mbata

6. [LinkedIn, Nov 2024] C10 Labs Winter Cohort: ReechOut, MyMonitor.Ai, Alpha Cure ... | https://www.linkedin.com/posts/matthewhcrane_episode-33-of-the-coworking-chronicles-has-activity-7427720782568665088-JJLo

7. [City of Philadelphia, retrieved 2026] City Announces Top Three Winners of the Philadelphia Regional Startup World Cup Pitch Competition | Department of Commerce | City of Philadelphia | https://www.phila.gov/2025-08-29-city-announces-top-three-winners-of-the-philadelphia-regional-startup-world-cup-pitch-competition/

8. [PubMed, retrieved 2026] Artificial intelligence for the automated single-shot assessment of psoriasis severity - PubMed | https://pubmed.ncbi.nlm.nih.gov/35739649/

9. [F6S, retrieved 2024] MyMonitor Corporation | https://www.f6s.com/company/mymonitor-corporation

10. [Legit.Health, retrieved 2026] Legit.Health - AI-Powered Dermatology Clinical Decision Support | https://legit.health/